TP53 and B-cell chronic lymphocytic leukemia: We show that mutations in TP53 can appear in a subset of monoallelic del(11q) CLL cases, conferring clonal advantage in vivo, and therefore a dismal clinical impact in terms of OS in this subgroup of CLL patients.